Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Australia: Monash profits hit by weak domestic market

Despite a 2.9% rise in net profits for the year to A$29.6 million (US$23.5 million) shares in Monash IVF Group, Australia’s second largest fertility treatment provider, declined almost 7% yesterday.

Revenues however declined 0.9% to A$155.2 million.

Even though the results were in line with guidance, the results were predominantly the result of strong cost control, rather than growth in the business.

The domestic market remained weak. The group Australian stimulated cycles decreased by 3.1% against overall Australian market decline of 0.8% and Monash’s stimulated cycles market share decreased from 22.9% to 22.4% with Australian patient treatments market share decreasing by 0.6% to 23.2%.

As a result of a low cost competitor entering the Victorian assisted reproductive services market Monash’s market share initially declined, however this trend reversed in Q4 recording a slight increase in market share.

The international market was a bright light. The KL Fertility business in Malaysia continued to deliver strong growth in patient treatments of 10.1% during the year. EBITDA increased to A$2.5 million as the benefits of strong volume growth were offset by a weakening currency and the upfront investment to support the transition to a new purpose-built clinic and day surgery to accommodate demand growth experienced in Malaysia. The group says that the transition to the new clinic was completed in May with positive initial feedback from patients and strong volume growth.

Looking forward CEO and managing director James Thiedeman said: “Monash IVF continues to focus on two key areas for growth and performance; to continue to leverage its heritage of scientific and technological excellence to maintain leading pregnancy success rates in the industry; and continue to capture growth through further acquisition opportunities in Australia and abroad based on its premium position in the sector”.

Monash shares are down more than 24% year-to-date. They closed at A$6.89.

Posted on: 22/08/2017 UTC+08:00


News

Singapore health technology start-up X-Zell has closed an oversubscribed Seed+ round led by German industrial service group, Deutsche Industrieanlagen.
Shanghai-based digital healthcare platform 111 Inc and Hainan Huluwa Pharmaceutical Group Co. have signed a strategic partnership agreement.
Malaysia's healthcare tourism industry is showing some encouraging signs of recovery after the government opened its borders in phases to international patients, beginning 1 July after a Recovery Movement Control Order began.
Elvie, a women’s health technology company is expanding into China and the US after securing following funding from HSBC in the UK.
South Korean medical devices manufacturer Medifiber has signed a deal with UK medtech company Copper Clothing fior the supply of copper-infused face masks to the UK market.
Petaling Jaya-based corporate healthcare benefits and wellness management platform HealthMetrics has raised $5 as part of a Series A funding in a round led by ACA Investments.
The Farrer Park Company has obtained a S$120 million green loan from United Overseas Bank Limited (UOB), the first such loan for a healthcare facility in Singapore.
The Malaysia Healthcare Travel Council has estimated that there has been a 75% reduction in medical tourism to Malaysia due to the Covid-19 pandemic.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed